ClinicalTrials.gg

Program

Paltusotine

Also written as “CRN00808”, “Randomized: 40 mg Paltusotine” and “Randomized: 80 mg Paltusotine”.

Its studies are mostly in Acromegaly · Serotonin Syndrome, led by Vertex Pharmaceuticals.

Furthest: phase 3, since Apr 6, 20219 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals91 open or runningphase 3since Apr 6, 2021Sep 5, 2017Aug 2027phase 3 · NCT07087054

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 5, 2017First study: phase 1 study in Healthy VolunteersFirst studyNCT03276858 · 99 enrolled · Australia
  2. Dec 27, 20182 phase 2 studies in AcromegalyNCT03792555, NCT03789656
  3. Jan 14, 2020Phase 1 study in Healthy VolunteersNCT04246749 · 11 enrolled · Netherlands
  4. Feb 6, 2020Phase 2 study in AcromegalyNCT04261712 · 43 enrolled · United States, Brazil, Germany and more
  5. Apr 6, 2021Phase 3 study in AcromegalyNCT04837040 · 58 enrolled · United States, Argentina, Belgium and more
  6. Jan 5, 2022Phase 3 study in AcromegalyNCT05192382 · 111 enrolled · United States, Argentina, Brazil and more
  7. Apr 27, 2022Phase 2 study in Serotonin SyndromeNCT05361668 · 36 enrolled · United States, Argentina, Brazil and more
  8. Jul 9, 2025Phase 3 study in Serotonin SyndromeNCT07087054 · 141 enrolled · United States, Argentina, Belgium and more

Ahead

  1. Aug 2027Primary completion: phase 3 study in Serotonin SyndromeNCT07087054

TargetBeta

CORT →SSTR2 →read by rule
“An orally bioavailable, nonpeptide somatostatin receptor type 2 (SST2; SSTR2) agonist, ”NCIt, by rule
“Somatostatin receptor 2 agonist”ChEMBL 37, by rule

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07087054Serotonin Syndrome · United States, Argentina, Belgium and more3Active, not recruitingAug 2027141
NCT05361668Serotonin Syndrome · United States, Argentina, Brazil and more2CompletedMar 7, 202436
NCT05192382Acromegaly · United States, Argentina, Brazil and more3TerminatedJan 20, 2024111
NCT04837040Acromegaly · United States, Argentina, Belgium and more3TerminatedJul 10, 202358
NCT04261712Acromegaly · United States, Brazil, Germany and more2TerminatedJun 30, 202643
NCT04246749Healthy Volunteers · Netherlands1CompletedOct 25, 201911
NCT03792555Acromegaly · United States, Brazil, Greece and more2CompletedJul 15, 202013
NCT03789656Acromegaly · United States, Brazil, Germany and more2CompletedAug 3, 202047
NCT03276858Healthy Volunteers · Australia1CompletedApr 30, 201899

How it is read

Names in the registry

  • “Paltusotine”, 6 entries
  • “CRN00808”, 2 entries
  • “Randomized: 40 mg Paltusotine”, 1 entry
  • “Randomized: 80 mg Paltusotine”, 1 entry
  • “[14C]-CRN00808”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.